Loading clinical trials...
Loading clinical trials...
A Phase I Clinical Trial for Gene Therapy in Infantile Malignant Osteopetrosis (IMO) to Evaluate the Safety and Preliminary Efficacy of Autologous CD34+ Enriched Cells Transduced With a LV Vector Encoding the TCIRG1 Gene
Conditions
Interventions
RP-L401
Locations
1
United States
University of California, Los Angeles
Los Angeles, California, United States
Start Date
November 19, 2020
Primary Completion Date
May 21, 2021
Completion Date
May 21, 2021
Last Updated
July 13, 2022
Lead Sponsor
Rocket Pharmaceuticals Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions